Dual Pathway Inhibition in Patients with Atherosclerosis with or without Heart Failure: Insights from the XATOA Registry
In a generalizable cohort of patients with atherosclerotic disease and HF, the use of DPI therapy is associated with outcomes similar to those observed in recent randomized controlled clinical trials.
Authors
- Robert C. Welsh (ORCID: https://orcid.org/0000-0003-2613-9142)
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Sebastian Debus (ORCID: https://orcid.org/0000-0002-8791-8644)
- Alain Gay (ORCID: https://orcid.org/0000-0002-0689-7168)
- Pishoy Gouda (ORCID: https://orcid.org/0000-0002-8158-4786)
- Keith A.A. Fox (ORCID: https://orcid.org/0000-0002-0140-2752)
- Kai Vogtländer (ORCID: https://orcid.org/0009-0008-3960-2101)
- Victor Aboyans (ORCID: https://orcid.org/0000-0002-0322-9818)
- Uwe Zeymer (ORCID: https://orcid.org/0000-0001-7077-283X)
Institutions
- University of Alberta (CA)
- Universität Hamburg (DE)
- Canadian VIGOUR Centre (CA)
- Stiftung Institut für Herzinfarktforschung (DE)
- Bayer (Germany) (DE)
- University of Edinburgh (GB)
Publication Details
- Journal
- CJC Open
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1016/j.cjco.2025.01.013
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Bayer